Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk?

Autor: Donald L. Yee, Shiu-Ki Hui, Saman K. Hashmi, Lakshmi Srivaths, Donald H. Mahoney, Mireya Paulina Velasquez
Rok vydání: 2017
Předmět:
Heart Defects
Congenital

Male
medicine.medical_specialty
Future studies
Adolescent
medicine.drug_class
Hypertension
Pulmonary

Hemorrhage
030204 cardiovascular system & hematology
Hemorrhagic Disorders
Risk Assessment
Gastroenterology
Young Adult
03 medical and health sciences
0302 clinical medicine
Acquired von Willebrand syndrome
hemic and lymphatic diseases
Internal medicine
von Willebrand Factor
medicine
Humans
In patient
Young adult
Child
Retrospective Studies
business.industry
Anticoagulant
Infant
Retrospective cohort study
Hematology
medicine.disease
Pulmonary hypertension
von Willebrand Diseases
Oncology
Child
Preschool

Hemorheology
Pediatrics
Perinatology and Child Health

Female
Medical emergency
Protein Multimerization
Shear Strength
business
circulatory and respiratory physiology
030215 immunology
Zdroj: Journal of Pediatric Hematology/Oncology. 39:121-125
ISSN: 1077-4114
DOI: 10.1097/mph.0000000000000738
Popis: There are conflicting reports on whether or not laboratory abnormalities in pediatric acquired von Willebrand syndrome (AVWS) predict bleeding manifestations in patients with cardiopulmonary disorders (CPD). We retrospectively reviewed charts of patients with AVWS and CPD (n=16) seen at Texas Children's Hospital from 2003 to 2012. The most common CPD were valve stenoses, ventricular septal defects, and pulmonary hypertension. All patients had loss of high molecular weight multimers. Fifteen (94%) patients presented with bleeding symptoms, with menorrhagia and epistaxis being the most common. Von Willebrand ristocetin cofactor activity (VWF:RCo), as well as the use of anticoagulant or antiplatelet medication, did not predict bleeding manifestations (P=0.70 and 0.84, respectively). VWF:RCo/VWF antigen (Ag) ratio of
Databáze: OpenAIRE